Notably, although 94.5% (360/380) of our baseline RET+ patients contained only RET fusions as the primary oncogenic driver of NSCLC, 21 patients (5.5%) harbored additional driver gene aberrations, including EGFR (11/21), KRAS (6/21), BRAF (2/21), ERBB2 (1/21) and ROS1 (1/21) (Additional file 3: Fig. S2a). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.